
PharmaBrain: Chatbot for Medical News Documents
Atacana needed a secure, offline medical chatbot capable of answering complex queries based on thousands of daily updated proprietary medical news reports and drug discovery advancements.
The Challenge
In the rapidly evolving pharmaceutical landscape, staying updated on medical advancements is a massive logistical challenge. Atacana required a solution that could synthesize information from thousands of documents—news reports, clinical trial updates, and drug discovery announcements—that were being added to their database daily.
The primary challenge was data privacy and the sheer volume of information. The solution required a completely offline deployment on local servers to protect proprietary medical data, while maintaining the processing speed necessary to handle thousands of daily document updates.
Our Solution
We engineered 'PharmaBrain' using a Retrieval-Augmented Generation (RAG) architecture built on a quantized Mixtral 8x7B model. By implementing 8-bit quantization, we reduced the memory footprint and processing time, enabling 5-7 second response latencies on local hardware.
Mixtral MoE Architecture
Built on a 46.7B parameter model that only uses 12.9B per token, providing significant speed advantages over comparable dense models.
LangChain Integration
Connected the LLM to the medical document database via LangChain, ensuring every answer is grounded in the latest research.
8-bit Quantization
Quantized to 8-bit to optimize for local server processing, achieving response times under 7 seconds.
Offline Security
Deployed entirely on local servers, guaranteeing zero proprietary medical data leakage to the cloud.
The Impact
The implementation of PharmaBrain has turned a static document repository into a real-time intelligence hub. Despite running locally, the system provides cited, accurate summaries of medical developments in under 7 seconds.
Performance
5-7 Seconds
Average response for RAG queries.
Compliance
100% Offline
Zero data exposure to public internet.
Project Showcase
System Performance Comparison
| # | User Question | AI Response | Expected Response |
|---|---|---|---|
| 1 | When did Sobi acquired of CTI BioPharma Corp.? | "Sobi acquired CTI BioPharma Corp. in June 2023." | Sobi announced CTI BioPharma acquisition on 10 May 2023 and completed of on 26 Jun 2023 |
| 2 | What are the latest updates from the Ph3 PACIFICA trial? | "The completion date for the Phase 3 PACIFICA trial is expected to be by the end of 2026." | Sobi mentioned that the enrollment in the confirmatory Ph3 PACIFICA trial is projected to be completed by the end of 2026 |
| 3 | When will the Imetelstat Ph3 IMpactMF clinical trial interim and final analysis is expected? | "The Imetelstat Ph3 IMpactMF clinical trial is expected to have an interim analysis in 2024, and a final analysis in 2025." | Interim analysis expected in H1 2025 and final analysis expected in H1 2026 |
Similar Case Studies
Start Your AI Consulting Services Partnership
Ready to take the first step towards unlocking opportunities, realizing goals, and embracing innovation? We're here and eager to connect.
Phone
+1 (737) 381-3933
Phone
+92 (314) 424-5425
USA
5900 Balcones Drive, STE 100 Austin TX 78731
Pakistan
585-H3, Johar Town, Lahore (Opp. Expo Center)

